Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | UBE2M | P61081 | 1/20 | 0.44 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.44 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577446 | 0.91 | GAA (0.51) | GAAKDM4ELMNASIGMAR1EGFR | |
| SCHEMBL5577734 | 0.91 | GAA (0.51) | GAAKDM4ELMNASIGMAR1BCHE | |
| SCHEMBL5577501 | 0.88 | ACHE (0.46) | GAAKDM4ELMNASIGMAR1ACHE | |
| SCHEMBL5577606 | 0.87 | GAA (0.54) | GAAKDM4ELMNASIGMAR1BCHE | |
| SCHEMBL5577390 | 0.84 | MEN1 (0.52) | GAAKDM4ELMNASIGMAR1CACNA1G | |
| SCHEMBL5577247 | 0.84 | GAA (0.48) | GAAKDM4ELMNASIGMAR1MCHR1 | |
| SCHEMBL5577248 | 0.83 | GAA (0.50) | GAAKDM4ELMNASIGMAR1BCHE | |
| SCHEMBL5577817 | 0.82 | SIGMAR1 (0.52) | GAAKDM4ELMNASIGMAR1 | |
| SCHEMBL5577354 | 0.82 | MCHR1 (0.51) | GAAKDM4ELMNASIGMAR1MCHR1 | |
| SCHEMBL5577356 | 0.81 | GAA (0.50) | GAAKDM4ELMNASIGMAR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | GAA 3806/4885KDM4E 4213/4885LMNA 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.